Additional file 15 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 15: Supplemental Figure 10. Examination of lung metastasis in a subcutaneous transplantation model using Rasa1-KO S1M cells

Additional file 13 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 13: Supplemental Figure 8. NF2 deficiency induces anoikis resistance via YAP activation

Additional file 2 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 2: Supplemental Table 1. Correlation between RASA1 immunoreactivity and clinicopathological parame ters in human GC tissues. P-value, Chi squared test

Additional file 17 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 17: Supplemental Figure 12. Analysis of Wnt inhibitor expression in response to Nf2-KO and YAP/TAZ signaling modulation

Additional file 8 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 8: Supplemental Figure 3. In vivo validation of target genes using the spleno-hepatic metastasis model

Additional file 5 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 5: Supplemental Table 4. Primer sequences for qPCR and RT-qPCR

Additional file 4 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 4: Supplemental Table 3. Information of drugs and chemicals used in this study

Additional file 20 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 20: Supplemental Figure 15. Immunohistochemical analysis following YAP and Bcl-xL inhibitor treatment in Nf2/Rasa1-double KO S1M peritoneal dissemination model

Additional file 1 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 1: Materials and methods

Additional file 6 of Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency

Additional file 6: Supplemental Figure 1. Establishment of the three-dimensional tumorsphere culture system